🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation

RecruitingPhase 4Ages 18 Years - anyAllFundació Institut de Recerca de l'Hospital de la …
NCT07273994 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

\--- The goal of this clinical trial is to learn if reduced doses of amiodarone can treat atrial fibrillation (AF) effectively while minimizing toxic side effects in patients with persistent AF after electrical cardioversion. The main questions it aims to answer are: * Can a reduced dose of amiodarone (100 mg/day) maintain sinus rhythm as effectively as the standard dose (200 mg/day) 12 months post electrical cardioversion? * What are the adverse effects of the standard and reduced doses of amiodarone during 12 months post electrical cardioversion? * How do genetic polymorphisms affect the efficacy and safety of amiodarone? * How do amiodarone plasma levels correlate with the maintenance of sinus rhythm and genetic polymorphisms? Researchers will compare the standard dose (200 mg/day) to the reduced dose (100 mg/day) to see if the reduced dose offers a better balance between efficacy

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria 1. Patients aged ≥ 18 years 2. Documented persistent atrial fibrillation (≥ 7 days in duration) 3. Electively referred for Electrical Cardioversion 4. Signed informed consent. Exclusion Criteria 1. Urgent electrical cardioversion 2. Atrial fibrillation post-cardiac surgery 3. Previous myocardial infarction 4. New York Heart Association (NYHA) Class IV heart failure 5. Left ventricular ejection fraction (LVEF) \<45% 6. Significant left ventricular hypertrophy (wall thickness ≥ 15mm) 7. Hyperthyroidism or hypothyroidism 8. Known hepatobiliary disease (acute hepatitis, cirrhosis...) or ALT/AST \> 3 x upper limit of normal (ULN) 9. Allergy, intolerance, or known hypersensitivity to study medications 10. Women of childbearing potential unwilling to use contraceptive measures and breastfeeding women. 11. Participation in another clinical trial involving investigational drugs 12. Life expectancy less than 12 months 13. Rheumatic mitral stenosis of any degree or severe mitral or aortic valve dysfunction. 14. Patients with contraindications to amiodarone, such as uncontrolled thyroid dysfunction, severe sinus bradycardia, second- or third-degree AV block without a pacemaker, and a history of amiodarone-induced pulmonary toxicity. 15. Patients in whom chronic amiodarone treatment previously failed to maintain sinus rhythm 16. Patients with abnormal baseline QTc (\>450 ms in males and \>470 in females) or abnormal ECG that precludes QTc assessment 17. Patients requiring concomitant medications that have a higher risk of QTc prolongation. 18. Patient do not have a smart mobile phone or do not know how to use it adequately.
💊

What it tests

  • Amiodarone Hydrochloride 200 MG
  • Amiodarone Hydrochloride 100 MG
📍

Where

1 site
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy